fig2

Figure 2. Establishment of human prostate cancer, PC-3/MRS-BLI, stably carrying multiplexed luciferase reporters. A: Schematic of PC-3/MRS-BLI. The 5κB motif contains five tandem repeats of the GGACTTTCC. The 5HRE motif contains five tandem repeats of the ACGTGG; B: Relative κB-FlucP bioluminescence intensity in PC-3/MRS-BLI cells treated with TNF-α (0.01, 0.1, 0.1, 5 ng/mL) for 6 h. n = 3, *P < 0.05 to the non-treated cells; C: Time-course changes of κB-FlucP bioluminescence intensity in TNF-α (5 ng/mL) treated PC-3/MRS-BLI cells. n = 3, *P < 0.05 to 0 h; D: Relative HRE-RlucP bioluminescence intensity in PC-3/MRS-BLI cells at various O₂ concentrations (1, 3, 5, 10, 21%) for 16 h. n = 3, *P < 0.05 to the cell under 21% O₂; E: Time-course changes of HRE-RlucP bioluminescence intensity in PC-3/MRS-BLI cells under 1% O₂. n = 3, *P < 0.05 to 0 h; F: Correlation of PC-3/MRS-BLI cell number and Cluc BL intensity. n = 3 for each cell number. MRS-BLI: multiplexed reporter system for bioluminescent imaging; Cluc: Cypridina luciferase; Fluc: Firefly luciferase; Rluc: Renilla luciferase; GPI: glycosylphosphatidylinositol; TNF-α: tumor necrosis factor-alpha; NF-κB: nuclear factor-kappa B; HIF: hypoxia-inducible factor